AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32150584 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation based Difficult Conversations Workshop
Number of subjects: 13
Study 32150584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 13
Study 34514692 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPA+SAXA+MET (10/5 mg)
Number of subjects: 382
Study 34514692 — intervention group
Group type: COMPARATOR
Intervention: GLIM+MET (1-6 mg)
Number of subjects: 382
Study 33326891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus antidepressant medications
Number of subjects: 452
Study 33326891 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medications
Number of subjects: 452
Study 33900493 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg three times daily)
Number of subjects: 70
Study 33900493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32059693 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization intervention based on Socializing Evidence for Participatory Action (SEPA)
Number of subjects: 5848
Study 32059693 — intervention group
Group type: COMPARATOR
Intervention: Usual dengue control practice
Number of subjects: 5848
Study 34057996 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted vitamin C levels (per 1 standard deviation increase)
Number of subjects: 15
Study 35354004 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Down Deep Breathing (HDDB)
Number of subjects: 41
Study 35354004 — intervention group
Group type: COMPARATOR
Intervention: Modified Valsalva Manoeuvre (VM)
Number of subjects: 41
Study 36272240 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality‐based Theory of Mind Intervention (VR‐ToMIS)
Number of subjects: 42
Study 36272240 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive‐VR)
Number of subjects: 42
Study 32161944 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 3576
Study 34260860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-pause (RP) training
Number of subjects: 28
Study 34260860 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-set (DS) training
Number of subjects: 28
Study 34260860 — intervention group
Group type: COMPARATOR
Intervention: Traditional resistance training (TRT)
Number of subjects: 28
Study 34260860 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups (RP, DS, TRT)
Number of subjects: 28
Study 33351478 — intervention group
Group type: EXPERIMENTAL
Intervention: PePS intervention
Number of subjects: 84
Study 33351478 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 84
Study 34676624 — intervention group
Group type: EXPERIMENTAL
Intervention: Active go/no-go training with sweet foods
Number of subjects: 46
Study 34676624 — intervention group
Group type: COMPARATOR
Intervention: Control go/no-go training with non-food cues
Number of subjects: 46
Study 32493319 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital triage tool implementation
Number of subjects: 0
Study 32493319 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (no intervention)
Number of subjects: 0
Study 35476316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg/day
Number of subjects: 130
Study 33401384 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Breaks® video intervention for 3-5 min daily at low-to-moderate intensity for three months
Number of subjects: 704
Study 33401384 — intervention group
Group type: COMPARATOR
Intervention: Normal routine (Control group)
Number of subjects: 704
Study 32968158 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly 3,000 IU cholecalciferol
Number of subjects: 96
Study 32968158 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly cholecalciferol (equivalent to 9,000 IU/week)
Number of subjects: 96
Study 32968158 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly placebo
Number of subjects: 96
Study 32968158 — intervention group
Group type: COMPARATOR
Intervention: Once-monthly placebo
Number of subjects: 96
Study 34103317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural therapy for insomnia (CBT‐I)
Number of subjects: 80
Study 34103317 — intervention group
Group type: COMPARATOR
Intervention: Single‐session sleep hygiene (SH) education
Number of subjects: 80
Study 34103317 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I and SH education
Number of subjects: 80
Study 32534584 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of methoxamine at 2 μg/kg/min
Number of subjects: 180
Study 32534584 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of normal saline (control)
Number of subjects: 180
Study 34155568 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50 mg/day
Number of subjects: 863
Study 34155568 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg/day
Number of subjects: 863
Study 34155568 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 200 mg/day
Number of subjects: 863
Study 34155568 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50-200 mg/day
Number of subjects: 863
Study 34155568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study 34155568 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (all dosages)
Number of subjects: 863
Study 35257600 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiretroviral drug as part of a combination antiretroviral treatment regimen
Number of subjects: 0
Study 35257600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33788473 — intervention group
Group type: EXPERIMENTAL
Intervention: Process management and evaluation
Number of subjects: 120
Study 33788473 — intervention group
Group type: COMPARATOR
Intervention: Conventional training mode
Number of subjects: 120
Study 36117083 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% Hydrogen Peroxide irrigation
Number of subjects: 50
Study 36117083 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study 34167538 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool (VDST) group
Number of subjects: 0
Study 34167538 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 0
Study 32216218 — intervention group
Group type: EXPERIMENTAL
Intervention: HoLEP + JSSD
Number of subjects: 110
Study 32216218 — intervention group
Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 110
Study 35045185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosnetupitant (FosNTP) 235 mg
Number of subjects: 102
Study 35045185 — intervention group
Group type: COMPARATOR
Intervention: Fosaprepitant (FosAPR) 150 mg
Number of subjects: 102
Study 34255080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate (LF-HC) diet
Number of subjects: 30
Study 34255080 — intervention group
Group type: COMPARATOR
Intervention: High-fat, low-carbohydrate (HF-LC) diet
Number of subjects: 30
Study 32371539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for three cycles, followed by three adjuvant cycles, in combination with definitive radiotherapy.
Number of subjects: 29
Study 32371539 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and radiotherapy
Number of subjects: 29
Study 33219482 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM vaginal gel (intravaginal daily dose for three 28-day periods)
Number of subjects: 216
Study 33219482 — intervention group
Group type: COMPARATOR
Intervention: Control (follow-up without intervention)
Number of subjects: 216
Study 33219482 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM vaginal gel
Number of subjects: 216
Study 33219482 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 216
Study 32400738 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (overweight and obese subjects)
Number of subjects: 111
Study 32400738 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (overweight and obese subjects with metabolic syndrome)
Number of subjects: 111
Study 32400738 — intervention group
Group type: COMPARATOR
Intervention: Group I (normal-weight subjects)
Number of subjects: 111
Study 35672894 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pulmonary rehabilitation training including pursed-lip breathing (PLB) training, abdominal breathing training, skeletal muscle training, and coughing and expectoration training.
Number of subjects: 72
Study 35672894 — intervention group
Group type: COMPARATOR
Intervention: Routine drug therapy, COPD knowledge education, and smoking cessation treatment (Control group).
Number of subjects: 72
Study 34111444 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglasses prescribed using standard subjective refraction (SR)
Number of subjects: 400
Study 34111444 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyeglasses prescribed using autorefraction (AR)
Number of subjects: 400
Study 34111444 — intervention group
Group type: COMPARATOR
Intervention: Comparison of spherical equivalents using SR and AR
Number of subjects: 400
Study 35772224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical one-handed chest compression (Test 2)
Number of subjects: 42
Study 35772224 — intervention group
Group type: COMPARATOR
Intervention: Conventional one-handed chest compression (Test 1)
Number of subjects: 42
Study 34176245 — intervention group
Group type: EXPERIMENTAL
Intervention: Suubi + Adherence intervention (n = 358)
Number of subjects: 702
Study 34176245 — intervention group
Group type: COMPARATOR
Intervention: Bolstered standard of care (BSOC; n = 344)
Number of subjects: 702
Study 33207743 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/ω‐3 PUFA‐enriched IVFE
Number of subjects: 92
Study 33207743 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil-based IVFE
Number of subjects: 92
Study 35443373 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of Remogliflozin 100mg + Vildagliptin 50mg (RV)
Number of subjects: 400
Study 35443373 — intervention group
Group type: COMPARATOR
Intervention: Empagliflozin 25mg + Linagliptin 5mg (EL)
Number of subjects: 400
Study 34574483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia problem-solving program (HPSP), 8-week duration, 90 min weekly sessions
Number of subjects: 71
Study 34574483 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 71
Study 34574483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia problem-solving program (HPSP)
Number of subjects: 71
Study 36047028 — intervention group
Group type: EXPERIMENTAL
Intervention: Durasul highly cross‐linked polyethylene
Number of subjects: 90
Study 36047028 — intervention group
Group type: COMPARATOR
Intervention: Sulene polyethylene
Number of subjects: 90
Study 32981401 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect video game training (KVG)
Number of subjects: 10
Study 32981401 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 10
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal ether concentration method
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet preparation method
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated sugar flotation method
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infection rate
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 12-14 years
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 9-11 years
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 6-8 years
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Single parasite infection
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple parasite infection
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Taenia spp.
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Giardia lamblia
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Schistosoma mansoni
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascaris lumbricoides
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Entamoeba coli
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymenolepis nana
Number of subjects: 134
Study 32913632 — intervention group
Group type: EXPERIMENTAL
Intervention: Entamoeba histolytica
Number of subjects: 134
Study 32574094 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 60
Study 32574094 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 60
Study 32574094 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study 34488691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle 1 (Basic)
Number of subjects: 1400
Study 34488691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle 1 + 2 (Enhanced)
Number of subjects: 1400
Study 34488691 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1400
Study 34488691 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 1400
Study 34365570 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional etching (CE) with pit and fissure sealants (PFS)
Number of subjects: 25
Study 34365570 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching (SE) agent 1 with PFS (SE1_PFS_Shofu)
Number of subjects: 25
Study 34365570 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching (SE) agent with PFS (SE_PFS_Kuraray)
Number of subjects: 25
Study 34365570 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental groups with PFS
Number of subjects: 25
Study 33819223 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Laryngeal Mask Airway (cLMA)
Number of subjects: 120
Study 33819223 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 120
Study 33819223 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprema Laryngeal Mask Airway (sLMA)
Number of subjects: 120
Study 33819223 — intervention group
Group type: EXPERIMENTAL
Intervention: Height/thyromental distance ratio
Number of subjects: 120
Study 33819223 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall predictive tests
Number of subjects: 120
Study 33197271 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg/weekly)
Number of subjects: 9901
Study 33197271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9901
Study 36477889 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.83 g protein kg body mass−1 day−1 (HIGH)
Number of subjects: 9
Study 36477889 — intervention group
Group type: COMPARATOR
Intervention: 1.20 g protein kg body mass−1 day−1 (MOD)
Number of subjects: 9
Study 36477889 — intervention group
Group type: COMPARATOR
Intervention: 0.94 g protein kg body mass−1 day−1 (LOW)
Number of subjects: 9
Study 32582177 — intervention group
Group type: EXPERIMENTAL
Intervention: HCMV+ infants
Number of subjects: 225
Study 32582177 — intervention group
Group type: COMPARATOR
Intervention: HCMV- infants
Number of subjects: 225
Study 32075475 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP1707 30 mg twice daily
Number of subjects: 72
Study 32075475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 33004310 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus financial incentives (up to $1000 contingent on individual reduction of tobacco usage)
Number of subjects: 135
Study 33004310 — intervention group
Group type: COMPARATOR
Intervention: Usual care (TSE education and quitline referrals)
Number of subjects: 135
Study 33004310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort's caregivers
Number of subjects: 135
Study 33004310 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired social network members in intervention cohort
Number of subjects: 135
Study 32715623 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) with albumin replacement
Number of subjects: 347
Study 32715623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham)
Number of subjects: 347
Study 34579560 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg/day)
Number of subjects: 175
Study 34579560 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 mg/day)
Number of subjects: 175
Study 34115064 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone substitute
Number of subjects: 10
Study 34115064 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic bone substitute
Number of subjects: 10
Study 34115064 — intervention group
Group type: COMPARATOR
Intervention: Control (incubated leukocytes only)
Number of subjects: 10
Study 34115064 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloplastic bone substitute
Number of subjects: 10
Study 34115064 — intervention group
Group type: EXPERIMENTAL
Intervention: Different masses of bone substitute (12.5 mg and 25 mg)
Number of subjects: 10
Study 35209731 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 17073
Study 35209731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17073
Study 32521096 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE)
Number of subjects: 119
Study 32521096 — intervention group
Group type: COMPARATOR
Intervention: Seeking Safety (SS)
Number of subjects: 119
Study 34607285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy
Number of subjects: 0
Study 34607285 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (four cycles)
Number of subjects: 0
Study 34607285 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs
Number of subjects: 0
Study 32171815 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video and patient information leaflet targeting misconceptions of topical corticosteroids
Number of subjects: 275
Study 35332505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐Held‐Skin‐to‐Skin (HHS)
Number of subjects: 195
Study 35332505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐Held‐Skin‐to‐Glove (HHG)
Number of subjects: 195
Study 35332505 — intervention group
Group type: COMPARATOR
Intervention: Hand‐not‐Held (HNH)
Number of subjects: 195
Study 32185840 — intervention group
Group type: EXPERIMENTAL
Intervention: ART with protease inhibitors (PI)
Number of subjects: 88
Study 32185840 — intervention group
Group type: COMPARATOR
Intervention: ART without protease inhibitors (PI)
Number of subjects: 88
Study 32185840 — intervention group
Group type: EXPERIMENTAL
Intervention: ART with protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Number of subjects: 88
Study 32185840 — intervention group
Group type: COMPARATOR
Intervention: ART without protease inhibitors (PI) after excluding women with detectable viral load and CD4+ T-cell count <200
Number of subjects: 88
Study 32185840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 36509889 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 461
Study 36509889 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 461
Study 36509889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 33755091 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine maintenance
Number of subjects: 80
Study 33755091 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 80
Study 33734883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandenberg and Kuse Mental Rotation Test (MRT)
Number of subjects: 39
Study 33734883 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anatomy knowledge
Number of subjects: 39
Study 33734883 — intervention group
Group type: COMPARATOR
Intervention: Other parameters
Number of subjects: 39
Study 33773357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for 24 weeks
Number of subjects: 120
Study 33773357 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy for 24 weeks
Number of subjects: 120
Study 33773357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy or supportive psychotherapy
Number of subjects: 120
Study 36351707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay counsellor-led problem-solving intervention supported by printed materials
Number of subjects: 32
Study 36351707 — intervention group
Group type: COMPARATOR
Intervention: Printed problem-solving materials alone (bibliotherapy)
Number of subjects: 32
Study 33466136 — intervention group
Group type: EXPERIMENTAL
Intervention: Care of Parkinson disease nurse specialist
Number of subjects: 0
Study 33466136 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35816306 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection and exercise therapy
Number of subjects: 100
Study 35816306 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection and exercise therapy
Number of subjects: 100
Study 34089525 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour (IOL)
Number of subjects: 160
Study 34089525 — intervention group
Group type: COMPARATOR
Intervention: Expectant care (Control)
Number of subjects: 160
Study 32858145 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anode tDCS (RA)
Number of subjects: 36
Study 32858145 — intervention group
Group type: COMPARATOR
Intervention: Left anode tDCS (LA)
Number of subjects: 36
Study 32858145 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 36